查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
真實世界證據（RWE）在塑造製藥業數位化未來中的作用
市場調查報告書
商品編碼
1764333

真實世界證據（RWE）在塑造製藥業數位化未來中的作用

The Role of Real-World Evidence in Shaping Pharma's Digital Future
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告深入探討了真實世界證據（RWE）在不斷發展的製藥領域中的關鍵作用，並重點關注了 RWE 在行業中日益成長的接受度和應用。報告深入分析了當前趨勢，重點關注醫療資料的數位化以及人工智慧（AI）在 RWE 生成中的整合。報告還深入分析了阻礙 RWE 應用的障礙，包括資料品質挑戰和地區接受度差異。

本報告也探討了製藥公司如何策略性地投資 RWE，以增強藥物開發和上市能力。報告進一步展望了 RWE 的未來發展，並強調了數位醫療技術在改變患者護理和監管決策方面的潛力。

關鍵問題

  • 1.目前真實世界證據（RWE）的使用和接受度有哪些趨勢？
  • 2.哪些障礙阻礙了RWE在製藥業的應用與接受？
  • 3.醫療資料數位化如何影響RWE的生成？
  • 4.人工智慧（AI）在RWE生成中扮演什麼角色？
  • 5.藥廠如何投資RWE？
  • 6.未來RWE生成將如何發展？

重點公司

  • Flatiron Health
  • UCB
  • MedExcellence Solutions
  • IQVIA
  • Aetion

部分參加專家名單

  • Flatiron Health 臨床資料管理負責人，美國
  • UCB 高級市場准入經理，澳洲
  • RWE 策略顧問，比利時
  • MedExcellence Solutions 董事總經理，比利時
  • 跨國製藥公司 RWE 數位平台負責人，美國
  • 生物製藥公司歐盟及數位資料轉型負責人，英國

方法論

檔案報告是基於獨立而簡潔的分析，這些分析源自於專有產業研究以及對產業意見領袖的深入訪談。報告深入分析了製藥企業高管需要了解的關鍵趨勢和市場發展，以應對未來的機會和挑戰。每份報告的重點都基於對二手文獻的回顧和已發現的知識差距。基於這項初步研究，制定了基於證據、專家指導的討論指南，以確保調查能夠回答最重要的問題。此外，制定了嚴格的篩選標準，以確保受訪者擁有就該主題發言所需的經驗、知識和地位。

報告有何特別之處？

FirstWordReports 是值得信賴的行業領導者，致力於製藥行業，為生物製藥專業人士和決策者提供深入、可操作的洞察。深厚的行業知識使能夠提供相關且有價值的洞察，幫助掌握新興趨勢，有效應對複雜挑戰。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖（KOL）的獨立、公正的見解，報告能夠提供所需的準確性和可靠性。獨家訪談和資料，以及持續的市場監測，讓能夠全面了解市場動態。報告涵蓋40多個活躍的疾病領域，包括關鍵意見領袖洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售與行銷、市場准入和其他領域問題的看法，有助於做出更明智的資料驅動決策，並在快速變化的行業中保持競爭力。

簡介目錄

This report delves into the pivotal role of real-world evidence (RWE) in the evolving pharmaceutical landscape, focusing on its increasing acceptance and application across the industry. It provides an in-depth analysis of current trends, highlighting the digitisation of healthcare data and the integration of artificial intelligence (AI) in RWE generation. Gain insights into the barriers that hinder RWE adoption, including data quality challenges and regional disparities in acceptance.

This report also explores how pharmaceutical companies are strategically investing in RWE to enhance drug development and market access. Additionally, it offers a forward-looking perspective on the future evolution of RWE, emphasising the potential for digital health technologies to transform patient care and regulatory decision making.

Key Questions Answered:

  • 1. What are the current trends in the use and acceptance of real-world evidence (RWE)?
  • 2. What barriers hinder the use and acceptance of RWE in the pharmaceutical industry?
  • 3. How is the digitisation of healthcare data impacting RWE generation?
  • 4. What role does artificial intelligence (AI) play in generating RWE?
  • 5. How are pharmaceutical companies investing in RWE?
  • 6. How will RWE generation evolve in the future?

Key Companies:

  • Flatiron Health
  • UCB
  • MedExcellence Solutions
  • IQVIA
  • Aetion

Partial List of Participating Experts:

  • Head, Clinical Data Management, Flatiron Health, US
  • Senior Market Access Manager, UCB, Australia
  • Strategic Consultant, RWE, Belgium
  • Managing Director, MedExcellence Solutions, Belgium
  • RWE Digital Platforms Lead, multinational pharma company, US
  • EU and Digital Data Transformation Lead, biopharma company, UK

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.